ScinoPharm Taiwan Ltd
TWSE:1789
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amerant Bancorp Inc
NYSE:AMTB
|
US |
ScinoPharm Taiwan Ltd
EPS (Diluted)
ScinoPharm Taiwan Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
EPS (Diluted)
NT$0
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
EPS (Diluted)
NT$3
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
EPS (Diluted)
NT$3
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
EPS (Diluted)
NT$18
|
CAGR 3-Years
16%
|
CAGR 5-Years
34%
|
CAGR 10-Years
45%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
EPS (Diluted)
NT$5
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
EPS (Diluted)
NT$0
|
CAGR 3-Years
63%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's EPS (Diluted)?
EPS (Diluted)
0.2
TWD
Based on the financial report for Dec 31, 2025, ScinoPharm Taiwan Ltd's EPS (Diluted) amounts to 0.2 TWD.
What is ScinoPharm Taiwan Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-14%
Over the last year, the EPS (Diluted) growth was -60%. The average annual EPS (Diluted) growth rates for ScinoPharm Taiwan Ltd have been -28% over the past three years , -14% over the past five years , and -14% over the past ten years .
